泛RAF抑制诱导急性髓系白血病细胞凋亡并与BCL2抑制协同作用
研究探索泛RAF抑制剂在急性髓系白血病(AML)中的疗效,发现泛RAF抑制而非MEK抑制在29%的AML样本中诱导细胞死亡,且对健康骨髓细胞无毒。机制上泛RAF抑制下调MCL1蛋白合成并在依赖MCL1存活的细胞中诱导凋亡。泛RAF与BCL2抑制剂联用可克服单药耐药,并在对阿扎胞苷+维奈克拉难治或复发的AML患者样本中协同诱导长期缓解。
要点
- 泛RAF抑制在29%的AML样本中诱导细胞死亡,对健康骨髓细胞无毒。
- 泛RAF抑制下调MCL1蛋白合成,在依赖MCL1的细胞中诱导凋亡。
- 泛RAF与BCL2抑制剂联用可克服单药耐药并在难治/复发AML样本中协同作用。
核心结论
- 泛RAF抑制单独或联合BCL2抑制是AML有前景的治疗策略。
研究设计与样本
- 研究探索泛RAF抑制剂在AML中的疗效,使用AML样本、AML细胞系及对阿扎胞苷+维奈克拉难治或复发的AML患者样本进行体外和离体实验。
主要发现
- 泛RAF抑制在29%的AML样本中诱导细胞死亡,对健康骨髓细胞无毒。
- 泛RAF抑制下调MCL1蛋白合成,并在依赖MCL1存活的细胞中诱导凋亡。
- 泛RAF与BCL2抑制剂联用可克服AML细胞系对单药的耐药,并在对阿扎胞苷+维奈克拉难治或复发的AML患者样本中协同诱导长期缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pan-RAF inhibitors have shown promise as antitumor agents in RAS and RAF mutated solid cancers. However, the efficacy of pan-RAF inhibitors in acute myeloid leukemia (AML) has not previously been explored. In AML, the RAS-RAF-MEK-ERK (MAPK) pathway is one of the most aberrantly activated oncogenic pathways, but previous targeting of this pathway by MEK inhibitors has not proven effective in clinical trials. Here we show that pan-RAF inhibition, but not MEK inhibition, induced cell death in 29% of AML samples while being nontoxic toward healthy bone marrow cells. Mechanistically, pan-RAF inhibition downregulated MCL1 protein synthesis and induced apoptosis in cells dependent on MCL1 for their survival. Furthermore, the combination of a pan-RAF and a BCL2 inhibitor overcame resistance to either compound alone in AML cell lines, as well as synergized and induced long-term responses ex vivo in AML patient samples relapsed or refractory to azacitidine + venetoclax treatment. Together, our results indicate that pan-RAF inhibition, alone or in combination with BCL2 inhibition, is a promising treatment strategy for AML.
引用
- Tambe M, Karjalainen E, Vähä-Koskela M, et al. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia. 2020. PMID: 32651543. doi:10.1038/s41375-020-0972-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。